Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

From April 2020, an existing successful Health Protection Research Unit will be bolstered by the addition of collaborators from the University of Oxford. Funded by NHIR, the next phase of the HPRU in Emerging and Zoonotic Infections will build on the work already done by the University of Liverpool, the Liverpool School of Tropical Medicine, and Public Health England.

Microscopic image of viruses © David Gregory & Debbie Marshall. Attribution 4.0 International (CC BY 4.0)

Several University of Oxford staff will collaborate as part of the unit, which has Professor Peter Horby as co-director. Professor Christl Donnelly (Statistics) will lead the theme on ‘Epidemiology and Risk Analysis’, and Professor Peter Simmonds (Experimental Medicine), is co-lead on the theme of ‘Pathogen and Vector Biology’.

‘Diagnostics and Host Response’ and ‘Patient Research for Public Health’ complete the set of major research themes which will be used to examine crucial questions related to High Consequence Infectious Diseases, and there will be a particular focus on zoonotic infections (those transmitted from animals to humans).  Emphasis on patient and public involvement will help to determine the most important research questions, and a programme of graduate studentships will support the training of the next generation of EZI researchers.

The full story is available on NIHR website

Similar stories

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.